LINCS MCF 10A Common Project: Rolling-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Dataset 3 of 15: End-point cell counts and normalized growth rate inhibition values for all technical replicates of biological replicate 3. - Dataset (ID:20311)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration (uM) | Time Point (hr) | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value | Assay Plate | Assay Well |
|---|---|---|---|---|---|---|---|---|---|---|
| MCF 10A-H2B-mCherry | Dasatinib | 3.1623 | 36.73 | 84.90 | 71 | 3254 | 0.0218 | -0.0334 | MN20160318_Q02 | C15 |
| MCF 10A-H2B-mCherry | Dasatinib | 3.1623 | 36.73 | 84.90 | 1096 | 3254 | 0.3368 | 0.6262 | MN20160318_Q02 | C15 |
| MCF 10A-H2B-mCherry | Dasatinib | 3.1623 | 36.73 | 84.90 | 37 | 3254 | 0.0114 | -0.1461 | MN20160318_Q02 | E18 |
| MCF 10A-H2B-mCherry | Dasatinib | 3.1623 | 36.73 | 84.90 | 1062 | 3254 | 0.3263 | 0.6165 | MN20160318_Q02 | E18 |
| MCF 10A-H2B-mCherry | Dasatinib | 3.1623 | 38.43 | 84.90 | 84 | 3459 | 0.0243 | -0.0020 | MN20160318_Q02 | C15 |
| MCF 10A-H2B-mCherry | Dasatinib | 3.1623 | 38.43 | 84.90 | 1120 | 3459 | 0.3237 | 0.6198 | MN20160318_Q02 | C15 |
| MCF 10A-H2B-mCherry | Dasatinib | 3.1623 | 38.43 | 84.90 | 40 | 3459 | 0.0116 | -0.1313 | MN20160318_Q02 | E18 |
| MCF 10A-H2B-mCherry | Dasatinib | 3.1623 | 38.43 | 84.90 | 1095 | 3459 | 0.3165 | 0.6130 | MN20160318_Q02 | E18 |
| MCF 10A-H2B-mCherry | Dasatinib | 3.1623 | 40.14 | 84.90 | 92 | 3682 | 0.0250 | 0.0149 | MN20160318_Q02 | C15 |
| MCF 10A-H2B-mCherry | Dasatinib | 3.1623 | 40.14 | 84.90 | 1123 | 3682 | 0.3050 | 0.6077 | MN20160318_Q02 | C15 |
| MCF 10A-H2B-mCherry | Dasatinib | 3.1623 | 40.14 | 84.90 | 43 | 3682 | 0.0117 | -0.1176 | MN20160318_Q02 | E18 |
| MCF 10A-H2B-mCherry | Dasatinib | 3.1623 | 40.14 | 84.90 | 1094 | 3682 | 0.2971 | 0.6000 | MN20160318_Q02 | E18 |
| MCF 10A-H2B-mCherry | Dasatinib | 3.1623 | 41.84 | 84.90 | 81 | 4003 | 0.0202 | -0.0084 | MN20160318_Q02 | C15 |
| MCF 10A-H2B-mCherry | Dasatinib | 3.1623 | 41.84 | 84.90 | 1124 | 4003 | 0.2808 | 0.5915 | MN20160318_Q02 | C15 |
| MCF 10A-H2B-mCherry | Dasatinib | 3.1623 | 41.84 | 84.90 | 43 | 4003 | 0.0107 | -0.1152 | MN20160318_Q02 | E18 |
| MCF 10A-H2B-mCherry | Dasatinib | 3.1623 | 41.84 | 84.90 | 1119 | 4003 | 0.2795 | 0.5902 | MN20160318_Q02 | E18 |
| MCF 10A-H2B-mCherry | Dasatinib | 3.1623 | 43.55 | 84.90 | 94 | 4287 | 0.0219 | 0.0182 | MN20160318_Q02 | C15 |
| MCF 10A-H2B-mCherry | Dasatinib | 3.1623 | 43.55 | 84.90 | 1138 | 4287 | 0.2654 | 0.5820 | MN20160318_Q02 | C15 |
| MCF 10A-H2B-mCherry | Dasatinib | 3.1623 | 43.55 | 84.90 | 56 | 4287 | 0.0131 | -0.0709 | MN20160318_Q02 | E18 |
| MCF 10A-H2B-mCherry | Dasatinib | 3.1623 | 43.55 | 84.90 | 1122 | 4287 | 0.2617 | 0.5781 | MN20160318_Q02 | E18 |
| MCF 10A-H2B-mCherry | Dasatinib | 3.1623 | 45.25 | 84.90 | 111 | 4539 | 0.0245 | 0.0478 | MN20160318_Q02 | C15 |
| MCF 10A-H2B-mCherry | Dasatinib | 3.1623 | 45.25 | 84.90 | 1175 | 4539 | 0.2588 | 0.5804 | MN20160318_Q02 | C15 |
| MCF 10A-H2B-mCherry | Dasatinib | 3.1623 | 45.25 | 84.90 | 63 | 4539 | 0.0139 | -0.0506 | MN20160318_Q02 | E18 |
| MCF 10A-H2B-mCherry | Dasatinib | 3.1623 | 45.25 | 84.90 | 1160 | 4539 | 0.2555 | 0.5769 | MN20160318_Q02 | E18 |
| MCF 10A-H2B-mCherry | Dasatinib | 3.1623 | 46.95 | 84.90 | 107 | 4952 | 0.0216 | 0.0402 | MN20160318_Q02 | C15 |